Guerbet Company Description

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab.

It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.

In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters.

Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables.

Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.

Guerbet SA

Country	France
Founded	1926
Industry	Medical Devices
Sector	Healthcare
Employees	2,920
CEO	David Hale

Contact Details

Address: 15, rue des Vanesses Villepinte, 93420 France
Phone	33 1 45 91 50 00
Website	guerbet.com

Stock Details

Ticker Symbol	GBT
Exchange	Euronext Paris
Reporting Currency	EUR
ISIN Number	FR0000032526
SIC Code	3844